MOD-GRF 1-29 + Ipamorelin (2/6 MG)

Additional Info

Properties

MOD-GRF 1-29

• Chemical Formula: C152H252N44O42
• Molecular Weight: 3367.95 g/mol
• Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
• Total Amount of the Active Ingredient: 8mg (1 vial)
• Shelf Life: 36 months

Ipamorelin

• Chemical Formula: C38H49N9O5
• Molecular Weight: 711.868 g/mol
• Sequence: Aib-His-D-2Nal-D-Phe-Lys

Shipping

• Available to USA and Canada
• For International Orders: In case of shipment seizure, we offer a 50% discount applicable on your next purchase. Please contact us for details.

Disclaimer

The information provided does not substitute medical advice, diagnosis, or treatment. For any medical concerns, consult your physician or qualified healthcare provider promptly. Delaying medical advice based on information seen or read is not recommended. We hold no responsibility or liability for the use of our research compounds and products, which are strictly intended for research purposes only. Personal use is not condoned.

Additional Label & Product Information

Essential Warning:

These chemicals are designated solely for research or laboratory use and are not FDA-approved for human consumption.

Usage Instructions:

• Avoid contact with skin and eyes. If contact occurs, rinse thoroughly with water.
• Seek medical assistance if feeling unwell or in case of accidental ingestion.
• Store the lyophilized peptide at room temperature upon receipt to maintain stability. Avoid frequent freeze-thaw cycles.

Product Disclaimer:

• This product is not intended to diagnose, treat, cure, or prevent any disease.
• Apply only as directed by specific research or laboratory protocols.

Resources

1. Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J. Investigation into the interaction between growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors in the rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Published in Endocrinology in June 1985;116(6):2643-9. doi: 10.1210/endo-116-6-2643. PMID: 2859987.
2. . Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the pioneering selective growth hormone secretagogue. Published in European Journal of Endocrinology in November 1998;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
3. Denson LA, Kim MO, Bezold R, Carey R, Osuntokun B, Nylund C, Willson T, Bonkowski E, Li D, Ballard E, Collins M, Moyer MS, Klein DJ. A randomized controlled trial investigating growth hormone in active pediatric Crohn disease. Published in Journal of Pediatric Gastroenterology and Nutrition in August 2010;51(2):130-9. doi: 10.1097/MPG.0b013e3181c992d6. PMID: 20453679; PMCID: PMC2910806.
4.  Ma Y, Zhang L, Edwards JN, Launikonis BS, Chen C. Growth hormone secretagogues safeguard mouse cardiomyocytes from in vitro ischemia/reperfusion injury by modulating intracellular calcium levels. Published in PLoS One in April 2012;7(4):e35265. doi: 10.1371/journal.pone.0035265. PMID: 22493744; PMCID: PMC3320867.
5. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 augment bone mineral content in adult female rats. Published in Journal of Endocrinology in June 2000;165(3):569-77. doi: 10.1677/joe.0.1650569. PMID: 10828840.
6.  Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: exploring the role of growth hormone secretagogues in modern management of body composition in hypogonadal males. Published in Translational Andrology and Urology in March 2020;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.
7. Adeghate E, Ponery AS. Mechanism of ipamorelin-induced insulin release from the pancreas of normal and diabetic rats. Published in Neuro Endocrinology Letters in December 2004;25(6):403-6. PMID: 15665799.
8.  Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study evaluating the Ghrelin mimetic ipamorelin for managing postoperative ileus in patients undergoing bowel resection. Published in International Journal of Colorectal Disease in December 2014;29(12):1527-34. doi: 10.1007/s00384-014-2030-8. Epub 2014 Oct 21. PMID: 25331030.
9.  Valcavi R, Jordan V, Dieguez C, John R, Manicardi E, Portioli I, Rodriguez-Arnao MD, Gomez-Pan A, Hall R, Scanlon MF. Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Published in Clinical Endocrinology (Oxford) in June 1986;24(6):693-8. doi: 10.1111/j.1365-2265.1986.tb01666.x. PMID: 3098458.